tafluprost

(redirected from Zioptan)

tafluprost

(ta-floo-prost) ,

Zioptan

(trade name)

Classification

Therapeutic: ocular hypotensive agent
Pharmacologic: prostaglandins
Pregnancy Category: C

Indications

Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Action

Acts as a prostaglandin analogues that decreases intraocular pressure by ↑ uveoscleral outflow.

Therapeutic effects

↓ intraocular pressure.

Pharmacokinetics

Absorption: Absorbed through cornea and is converted to the active metabolite tafluprost acid.
Distribution: Unknown.
Metabolism and Excretion: Further metabolized and eliminated.
Half-life: Unknown.

Time/action profile (↓ in intraocular pressure)

ROUTEONSETPEAKDURATION
Ophthwithin 2–4 hr12 hr24 hr

Contraindications/Precautions

Contraindicated in: Pediatric: Avoid use in children due to unknown safety of chronic ↑ pigmentation.
Use Cautiously in: Aphakia, pseudoaphakia with a torn posterior lens capsule; Known risk factors for macular edema; Obstetric: Women with child-bearing potential should practice adequate contraception; Lactation: Use cautiously in nursing women.

Adverse Reactions/Side Effects

Ear, Eye, Nose, Throat

  • conjunctival hyperemia (most frequent)
  • blurred vision
  • cataract
  • permanent iris pigmentation
  • eyelid pigmentation
  • lash pigmentation/increased thickness/↑ number
  • macular edema
  • ocular stinging/irritation

Interactions

Drug-Drug interaction

Note noted.

Route/Dosage

Ophthalmic (Adults) One drop once daily (into conjunctival sac) in the evening into affected eye(s).

Availability

Ophthalmic solution : 0.0015% in 0.3 mL single-use containers

Nursing implications

Nursing assessment

  • Measure intraocular pressure periodically during therapy.

Potential Nursing Diagnoses

Readiness for enhanced knowledge, related to medication regimen (Patient/Family Teaching)

Implementation

  • Ophthalmic: Wash hands prior to instillation. Pull lower lid downward and look up. Instill 1 drop in conjunctival sac each evening. Each unit is for one-time use; discard after using. Store unopened foil pouches in refrigerator. Do not open pouch until ready to use.
    • If used with other ophthalmic medications, administer at least 5 min apart.

Patient/Family Teaching

  • Instruct patient to use drops as directed. Do not use more than 1 drop daily; may increase intraocular pressure. Do not use for a condition for which it was not prescribed. Do not share with others, even if they have the same symptoms; may cause harm.
  • Advise patient to read the Patient Information Leaflet prior to initiating therapy and with each Rx refill in case of changes.
  • Inform patient of potential side effects including brownish color of the iris; may be permanent. Also, darkening of the eyelid, increasing length, thickness, color, or number of eyelashes, and hair growth on eyelids; usually reversible.
  • Advise patient to notify health care professional if eye injury, eye infection, sudden loss of vision, eye surgery, swelling and redness around eye, or problems with eyelids occur.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patient use adequate contraception during therapy and to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.

Evaluation/Desired Outcomes

  • Reduction of intraocular pressure.
References in periodicals archive ?
Our study forecasts sales of 27 marketed drugs, including these brands: - Lucentis - Eylea - Restasis - Vigamox - Pataday/ Patanol - Jetrea - Lumigan and Ganfort - Xalatan/Xalacom - Zioptan - Cravit Discover how high revenues can go.
Our study forecasts sales of 27 marketed drugs, including these brands: -- Lucentis -- Eylea -- Restasis -- Vigamox -- Pataday/ Patanol -- Jetrea -- Lumigan and Ganfort -- Xalatan/Xalacom -- Zioptan -- Cravit
These include glaucoma treatment pill Zioptan, hepatitis C drug Victrelis, and an extended version of its combination type-2 diabetes pill, Janumet XR.
Received FDA approval for ZIOPTAN (tafluprost ophthalmic solution) 0.
ZIOPTAN (pronounced zye-OP-tan) is approved for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension.
The approval of ZIOPTAN will provide a new, effective option to lower IOP," said George L.
The FDA approval of ZIOPTAN was based on efficacy and safety results from five controlled clinical studies of up to two years in 905 patients.
In clinical studies of up to two years in duration, ZIOPTAN, dosed once-daily in the evening lowered IOP at 3 and 6 months by 6-8 mmHg and 5-8 mmHg respectively, from a baseline pressure of 23-26 mmHg (mmHg = millimeters of mercury, a measurement of fluid pressure in the eye).
Merck anticipates that ZIOPTAN will be available to customers in March.
Selected Important Safety Information about ZIOPTAN
Pigmentation is expected to increase as long as ZIOPTAN is administered.
15 Merck: Zioptan Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 4.